Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.

Ji L, Onishi Y, Ahn CW, Agarwal P, Chou CW, Haber H, Guerrettaz K, Boardman MK

Journal of diabetes investigation14 Sept 2012Cited by 63 (Europe PMC)

PMID24843631PMCIDPMC4019288DOI10.1111/j.2040-1124.2012.00238.xPepBankPUB-24843631

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Asian patients with type 2 diabetes, weekly exenatide reduced HbA1c more than twice-daily exenatide.
In plain wordsIn Asian patients with diabetes, weekly exenatide reduced HbA1c more than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c
Study
n = 681
Comparator
Exenatide twice daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c treatment difference
−0.31%
weekly versus twice daily
Source sentences
Summary
EQW was superior to EBID on HbA1c measures at week 26 (Least-squares mean treatment difference: -0.31% [95% confidence interval -0.49, -0.14%]).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363101
02HumanRandomized controlled trialEfficacy outcome
In Asian patients with diabetes, more patients achieved HbA1c ≤7.0% with weekly than twice-daily exenatide.
In plain wordsIn Asian patients with diabetes, more patients reached HbA1c ≤7.0% with weekly than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHbA1c at most 7.0%
Study
n = 681
Comparator
Exenatide twice daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
More EQW-treated patients achieved target HbA1c ≤7.0% (P = 0.003), ≤6.5% (P < 0.001), or ≤6.0% (P = 0.003).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363102
03HumanRandomized controlled trialEfficacy outcome
In Asian patients with diabetes, more patients achieved HbA1c ≤6.5% with weekly than twice-daily exenatide.
In plain wordsIn Asian patients with diabetes, more patients reached HbA1c ≤6.5% with weekly than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHbA1c at most 6.5%
Study
n = 681
Comparator
Exenatide twice daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
More EQW-treated patients achieved target HbA1c ≤7.0% (P = 0.003), ≤6.5% (P < 0.001), or ≤6.0% (P = 0.003).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363103
04HumanRandomized controlled trialEfficacy outcome
In Asian patients with diabetes, more patients achieved HbA1c ≤6.0% with weekly than twice-daily exenatide.
In plain wordsIn Asian patients with diabetes, more patients reached HbA1c ≤6.0% with weekly than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHbA1c at most 6.0%
Study
n = 681
Comparator
Exenatide twice daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
More EQW-treated patients achieved target HbA1c ≤7.0% (P = 0.003), ≤6.5% (P < 0.001), or ≤6.0% (P = 0.003).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363104
05HumanRandomized controlled trialEfficacy outcome
In Asian patients with diabetes, weekly exenatide reduced fasting glucose more than twice-daily exenatide.
In plain wordsIn Asian patients with diabetes, weekly exenatide reduced fasting glucose more than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting serum glucose
Study
n = 681
Comparator
Exenatide twice daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Fasting serum glucose reductions were greater among EQW-treated patients (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363105
06HumanRandomized controlled trialEfficacy outcome
In Asian patients with diabetes, blood glucose profiles improved in both weekly and twice-daily exenatide groups.
In plain wordsIn Asian patients with diabetes, blood glucose profiles improved in both exenatide groups.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedBlood glucose profiles
Study
n = 681
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly or 10 μg twice daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Blood glucose profiles improved in both treatment groups (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363106
07HumanRandomized controlled trialEfficacy outcome
In Asian patients with diabetes, both exenatide regimens reduced weight, but weight loss was smaller with weekly than twice-daily dosing.
In plain wordsIn Asian patients with diabetes, both exenatide regimens reduced weight, but weekly dosing produced less weight loss than twice-daily dosing.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight loss
Study
n = 681
Comparator
Exenatide twice daily
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Weight loss occurred with both treatments, but was greater with EBID.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363107
08HumanRandomized controlled trialSafety outcome
In Asian patients with diabetes, nausea was less frequent with weekly than twice-daily exenatide.
In plain wordsIn Asian patients with diabetes, nausea was less frequent with weekly than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNausea
Study
n = 681
Comparator
Exenatide twice daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Injection-site induration was more frequent with EQW, whereas nausea, vomiting and hypoglycemia were less frequent.
3 context sentences(design, population, supporting numbers)
Summary · context
Adverse events (≥10%, either group) were nausea, injection-site induration, dyslipidemia and vomiting.
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363108
09HumanRandomized controlled trialSafety outcome
In Asian patients with diabetes, injection-site induration was more frequent with weekly than twice-daily exenatide.
In plain wordsIn Asian patients with diabetes, injection-site hardening was more frequent with weekly than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInjection-site induration
Study
n = 681
Comparator
Exenatide twice daily
Outcome group
Adverse events · Skin and wound
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Injection-site induration was more frequent with EQW, whereas nausea, vomiting and hypoglycemia were less frequent.
3 context sentences(design, population, supporting numbers)
Summary · context
Adverse events (≥10%, either group) were nausea, injection-site induration, dyslipidemia and vomiting.
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363109
10HumanRandomized controlled trialSafety outcome
In Asian patients with diabetes, dyslipidemia was an adverse event reported in at least 10% of either exenatide group.
In plain wordsIn Asian patients with diabetes, abnormal blood lipids occurred in at least 10% of one or both exenatide groups.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedDyslipidemia
Study
n = 681
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Incidence of dyslipidemia
≥ 10%
either exenatide group
Source sentences
Summary
Adverse events (≥10%, either group) were nausea, injection-site induration, dyslipidemia and vomiting.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363110
11HumanRandomized controlled trialSafety outcome
In Asian patients with diabetes, vomiting was less frequent with weekly than twice-daily exenatide.
In plain wordsIn Asian patients with diabetes, vomiting was less frequent with weekly than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseVomiting
Study
n = 681
Comparator
Exenatide twice daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Injection-site induration was more frequent with EQW, whereas nausea, vomiting and hypoglycemia were less frequent.
3 context sentences(design, population, supporting numbers)
Summary · context
Adverse events (≥10%, either group) were nausea, injection-site induration, dyslipidemia and vomiting.
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363111
12HumanRandomized controlled trialSafety outcome
In Asian patients with diabetes, hypoglycemia was less frequent with weekly than twice-daily exenatide.
In plain wordsIn Asian patients with diabetes, low blood sugar was less frequent with weekly than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHypoglycemia
Study
n = 681
Comparator
Exenatide twice daily
Outcome group
Adverse events · Metabolic and weight
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Injection-site induration was more frequent with EQW, whereas nausea, vomiting and hypoglycemia were less frequent.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363112
13HumanRandomized controlled trialSafety outcome
In Asian patients with diabetes, one major hypoglycemia episode occurred with twice-daily exenatide.
In plain wordsIn Asian patients with diabetes, one major low-blood-sugar episode occurred with twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableMajor hypoglycemia with twice-daily exenatide
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
10 μg twice daily · 26 weeksAs given in this study (human).
Measurements
Major hypoglycemia episodes
1 episode
exenatide twice daily
Source sentences
Summary
One episode each of major hypoglycemia (EBID) and pancreatitis (EQW) were reported.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363113
14HumanRandomized controlled trialSafety outcome
In Asian patients with diabetes, one pancreatitis episode occurred with weekly exenatide.
In plain wordsIn Asian patients with diabetes, one pancreatitis episode occurred with weekly exenatide.
Peptide
Exenatide (exendin-4)
Outcome
Not applicablePancreatitis with weekly exenatide
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
2 mg once weekly · 26 weeksAs given in this study (human).
Measurements
Pancreatitis episodes
1 episode
exenatide once weekly
Source sentences
Summary
One episode each of major hypoglycemia (EBID) and pancreatitis (EQW) were reported.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs).
Summary · context
Patients added 2 mg EQW or 10 μg EBID to current OAMs.
Report a problemFND-2484363114

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00917267

A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

AstraZenecan = 691Jul 2009 to Apr 2011

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 9 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.